ALFA Finder| Revenue growth | 9% YoY for Q4 FY26; FY26 flat at ₹1798 Cr. |
|---|---|
| Margins | EBITDA margins impacted by new facility ramp-up costs and energy inflation. |
| Demand visibility | Strong CDMO pipeline; 54 active projects with 35 in commercial stage. |
| Management confidence | High for long-term CDMO growth and Atali phase 1 ramp-up. |
Growth
FY26 revenue hit ₹1798 Cr; EBITDA at ₹406 Cr. CDMO segment grew 32% YoY.
Outlook
Guiding 15-18% revenue/EBITDA growth for next 3-4 years. CDMO projected to grow 40-50% in FY27.
Risks
Geopolitical tensions in West Asia affecting logistics/energy costs; pricing pressure in API intermediates.
Earnings Call filed with BSE, NSE: AARTIPHARM. Summary written with AI assistance from the document.
Aarti Pharmalabs Ltd: key numbers
- Share price
- ₹923.50
- Market cap
- ₹8,374 Cr
- Revenue (annual)
- ₹1,819 Cr
- Net profit (annual)
- ₹174.7 Cr
- P/E (TTM)
- 32.6×Sector 43.8×
- Promoter holding
- 39.66%-3.20% QoQ
- FII holding
- 8.16%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Aarti Pharmalabs Ltd
All →Aarti Pharmalabs Earnings Call Transcript: Key Takeaways
Aarti Pharmalabs delivered record quarterly revenue driven by strong CDMO growth, though aggressive capex is temporarily elevating debt and working capital.
- Call
- Guides 45% growth
Aarti Pharmalabs Investor Presentation: Key Takeaways
Q2 FY27 standalone revenue INR 6,126Mn (+46.8% YoY), EBITDA INR 1,358Mn (22.2% margin), PAT INR 658Mn (+180% YoY). H1 revenue +44.7%. Xanthine capacity expansion and Atali capex drive growth.
Aarti Pharmalabs Management Change
Aarti Pharmalabs accepted CFO Piyush Lakhani's resignation, effective 30 October 2026, and appointed Vibha Thakker as CFO from 31 October 2026. The filing records a senior management change with no monetary amount.
Aarti Pharmalabs Q2 FY27 Results: Net Profit ₹71.5 Cr, Up 248.8% YoY
Aarti Pharmalabs Ltd reported revenue from operations of ₹610.5 Cr (+45.9% YoY) and net profit of ₹71.5 Cr (+248.8% YoY) for Q2 FY27.
- Key figure
- Net profit ₹71.5 Cr · +248.8% YoY
Aarti Pharmalabs Other Announcement
Aarti Pharmalabs has intimated under Regulation 46 that it revamped its website at the existing URL to improve design and accessibility. The notice has no financial or business substance.
Aarti Pharmalabs Employee Stock Options
Aarti Pharmalabs granted 850 stock options to employees under its PSOP 2023 at Rs.5 exercise price. This is an employee incentive grant, not a capital raise.